The Centers for Medicare & Medicaid Service’s proposed update for Medicare Advantage and Part D prescription drug programs in calendar year 2017 includes, on balance, “fair and sustainable rates to help ensure patient access to vital health care services,” AHA said in comments submitted today. “However, we have concerns about several of the proposed policies, such as the rapid increase in the proportion of risk scores based on incomplete encounter data,” wrote AHA Executive Vice President Tom Nickels. The letter addresses several areas of importance to hospitals and health systems, especially those that offer MA and Part D plans, such as proposed changes to the risk-adjustment model, star-rating program and risk scoring.

Related News Articles

Headline
The departments of Health and Human Services and the Treasury today approved a Section 1332 waiver for Oregon to implement a five-year reinsurance…
Headline
President Trump today issued an executive order directing the departments of Treasury, Labor and Health and Human Services to consider proposing regulations or…
Headline
Baxter Healthcare Corp., in coordination with the Food and Drug Administration, has agreed to temporarily import certain intravenous drug products, such…
Headline
President Trump yesterday named Eric Hargan as Acting Secretary of Health and Human Services. Confirmed as HHS deputy secretary last week, Hargan previously…
Headline
Hospitals generally support the proposed cancellation of the cardiac and Surgical Hip and Femur Fracture Treatment bundling program and Comprehensive Care for…
Headline
Twenty-three organizations, including the AHA, Friday urged the Centers for Medicare & Medicaid Services to suspend implementation of new draft Medicare…